Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Lung immaturity is a major issue in neonatal unit.The surfactant administration improves the pulmonary prognosis in premature infants with hyaline membrane disease who escape continuous positive airway pressure (CPAP).
This surfactant had been administered at 5h25min of life in Saint Etienne from 2016 to 2019.
Studies suggest that the earlier the surfactant is administered, the more it can reduce the rate of bronchodysplasia and mortality. And some studies show a pulmonary ultrasound could help to administrate the surfactant earlier This is why a new faster strategy for diagnosing preterms needing surfactant will be usefulness and have been done in Saint-Etienne since 2021 thanks to a ultrasound score (LUS).
This current study analyzes the impact of early Lungs Ultrasounds which use a semi-quantitative assessment : the Lung Ultrasound Score (LUS), in preterms <33 weeks on the time to surfactant administration.
The current hypothesis is that Lung Ultrasound can increase the number of preterms with surfactant replacement within the first 3 hours of life.
This is a prospective, comparative, observational trial between two different cohorts : the last 6 months of 2019 (without Score LUS) versus the first 6 months of 2021 (with Score LUS).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Surfactant administration without using score LUS | It is a retrospective cohort : preterm newborns from august 2019 to december 2019 needed a surfactant administration. The surfactant was administrated only if the fraction of inspired oxygen (FiO2) >30% among the Guidelines of 2019 |
| |
| Surfactant administration using score LUS | It is a prospective cohort : preterm newborns from january 2021 to juin 2020 needed a surfactant administration. The surfactant is administrated if FiO2 >30% OR if score LUS >8/18 among the literature |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Surfactant administration until 2020 | Drug | Surfactant is administrated if Fi02 >30% among the Guidelines of 2019 |
|
| Measure | Description | Time Frame |
|---|---|---|
| administration time frame (min of life) | Time from birth to surfactant administration | day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| FiO2 maximum | Collect in medical record.: the maximal value of FiO2 from birth to one week of life | Week 1 |
| delay from FiO2 maximum to FiO2 < 21% | Collect in medical record |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
preterm newborns < 33 weeks with Respiratory Distress Syndrom needed surfactant administration
Date of birth from 01/08/19 to 31/12/19 and from 01/01/21 to 30/06/21
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Aurelie CANTAIS, MD | CHU de Saint-Etienne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chu de Saint-Etienne | Saint-Etienne | 42055 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Surfactant administration since 2021 | Drug | Surfactant is administrated if Fi02 >30% OR if score LUS >8/18 among the literature |
|
|
| Week 4 |
| Ventilation time (day) | Collect in medical record : number of day using a ventilation | Week 4 |
| Ventilation support | Collect in medical record : using a invasive ou a non invasive ventilation | Week 4 |
| Bronchodysplasia rate | Collect in medical record. | Week 4 |
| ID | Term |
|---|---|
| D047928 | Premature Birth |
| ID | Term |
|---|---|
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided